HomeNewsNews PharmamelCapital Cell invests in Pharmamel for the development of new drugs based on melatonin

Capital Cell invests in Pharmamel for the development of new drugs based on melatonin

Capital Cell invests in Pharmamel for the development of new drugs based on melatonin

Capital Cell is Europe’s first online investment platform specialized in health and biotechnology, one of the world’s most profitable sectors with significant social impact. The Granada-based startup Pharmamel is currently undergoing a capital increase to tackle the final clinical and regulatory phases of the drug.

After achieving promising results in two phase II clinical trials, Pharmamel has the perfect drug candidate to address this disease. The company is already working on the ‘Road Map’ for its listing on the American market, with preliminary agreements already established with registered advisors, investment banking, and venture capital funds.

If you would like more information about the results, please contact us.